AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Avricore Health Announces Stock Option Grant for 4,100,000 Common Shares
ByAinvest
Saturday, Jun 14, 2025 1:09 am ET1min read
Avricore Health Inc. has granted stock options for 4,100,000 common shares to its directors, officers, employees, and consultants at a price of CAD $0.05 per share. The options will vest quarterly and expire in 5 years. This move is part of Avricore's strategy to advance pharmacy practice and patient care through its flagship offering HealthTab, a network of rapid testing devices in community pharmacies.
Avricore Health Inc. (TSXV: AVCR), a pharmacy service innovator focused on advancing pharmacy practice and patient care, has announced the granting of stock options to its directors, officers, employees, and consultants. The company's board of directors approved the issuance of 4,100,000 common shares at an exercise price of CAD $0.05 per share [1].The options will vest quarterly and expire in five years, provided that the optionees continue to act as directors, officers, employees, or consultants of the company. This move is part of Avricore's strategy to incentivize and retain key personnel as it continues to develop and expand its flagship offering, HealthTab, a network of rapid testing devices in community pharmacies [1].
HealthTab combines best-in-class point-of-care technologies with a secure, cloud-based platform, enabling lab-accurate results from a few drops of blood and real-time data reporting. The system includes up to 23 key biomarkers for chronic disease management and has recently added capabilities for bacterial and viral tests, such as strep and COVID-19 [1].
Avricore Health Inc. aims to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies. The HealthTab network model empowers pharmacists to play a greater role in primary care delivery while reducing costs and waiting times and providing multiple revenue streams [1].
The company's stock price has seen recent growth, with a 10% increase on June 13, 2025, closing at CAD $0.0550 [2].
References:
[1] https://www.streetinsider.com/Globe+Newswire/Avricore+Grants+Options/24937445.html
[2] https://ca.finance.yahoo.com/quote/AVCR.V/analysis/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet